Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C-->T polymorphism in MTHFR.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/19952781
Conclusion of this study
Riboflavin is effective in reducing blood pressure specifically in patients with the MTHFR 677 TT genotype. The findings, if confirmed, may have important implications for the prevention and treatment of hypertension.
Supplements analyzed in this study
|
Health conditions analyzed in this study
No health conditions information for this study.Functions related to this study
|
||
|
Body systems related to this study
Cardiovascular System |